头孢地罗和其他比较物对碳青霉烯耐药革兰氏阴性杆菌的体外敏感性：来自印度的研究。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2025-01-31 DOI:10.1016/j.ijmmb.2025.100793

Akansha Didwania , Sarita Mohapatra , Deepak Kocher , Hitender Gautam , Priyanka Kumari , Arvind Kumar , Manish Soneja , Naval K. Vikram , Seema Sood , Benu Dhawan , Bimal Kumar Das , Rama Chaudhry , Manoranjan Mahapatra , Naveet Wig , Arti Kapil

{"title":"头孢地罗和其他比较物对碳青霉烯耐药革兰氏阴性杆菌的体外敏感性：来自印度的研究。","authors":"Akansha Didwania , Sarita Mohapatra , Deepak Kocher , Hitender Gautam , Priyanka Kumari , Arvind Kumar , Manish Soneja , Naval K. Vikram , Seema Sood , Benu Dhawan , Bimal Kumar Das , Rama Chaudhry , Manoranjan Mahapatra , Naveet Wig , Arti Kapil","doi":"10.1016/j.ijmmb.2025.100793","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Cefiderocol is a parenteral catechol-type siderophore cephalosporin, which has been approved for the treatment of Gram-negative bacterial infections. Its activity among the carbapenem-resistant Gram-negative bacilli (CR-GNBs) in India is largely unknown.</div></div><div><h3>Methodology</h3><div>We tested <em>in-vitro</em> susceptibility of cefiderocol in 84 CR-GNB [ carbapenem-resistant <em>Acinetobacter baumannii</em> (CRAB), carbapenem-resistant <em>Pseudomonas aeruginosa</em> (CRPA), carbapenem-resistant <em>Escherichia coli</em> (CREC) and carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP)] by broth microdilution (BMD) and disc diffusion (DD) using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and concordance of DD was compared with BMD. Cefiderocol susceptibility was evaluated based on the presence of <em>bla</em><sub>NDM</sub> and <em>bla</em><sub>OXA-48</sub> genes.</div></div><div><h3>Results</h3><div>Following CLSI and EUCAST breakpoints, 76.2% [CRKP: 95.65% (22/23); CRPA: 80% (16/20); CREC: 65% (13/20); CRAB: 61.9% (13/21)] and 52.3% [ CRKP: 82.6% (19/23); CRPA: 50% (10/20); CREC: 20% (4/20)] of CR-GNBs were observed susceptible to cefiderocol, respectively. The susceptibility to cefiderocol was seen higher with lower MIC<sub>50</sub> and MIC<sub>90</sub> values for CRKP [1 μg/ml; 4 μg/ml ] and CRPA [2 μg/ml; 8 μg/ml ] in comparison to the other two groups of organisms. The categorical agreement between BMD and DD was found between 90% and 100% for all organisms. Cefiderocol susceptibility among the isolates harbouring <em>bla</em><sub>NDM</sub>, <em>bla</em><sub>OXA-48</sub>, and both <em>bla</em><sub>NDM</sub> and <em>bla</em><sub>OXA-48</sub> genes was observed 75% (24/32); 100% (3/3); and 66.6% (4/6), respectively.</div></div><div><h3>Conclusion</h3><div>Cefiderocol demonstrated high <em>in-vitro</em> activity against CRKP and CRPA isolates from India with lower MIC<sub>50</sub> and MIC<sub>90</sub> irrespective of the presence of <em>bla</em><sub>NDM</sub> and <em>bla</em><sub>OXA-48</sub> genes.</div></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"54 ","pages":"Article 100793"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In-vitro susceptibility of cefiderocol and other comparators in carbapenem-resistant Gram-negative bacilli: A study from India\",\"authors\":\"Akansha Didwania , Sarita Mohapatra , Deepak Kocher , Hitender Gautam , Priyanka Kumari , Arvind Kumar , Manish Soneja , Naval K. Vikram , Seema Sood , Benu Dhawan , Bimal Kumar Das , Rama Chaudhry , Manoranjan Mahapatra , Naveet Wig , Arti Kapil\",\"doi\":\"10.1016/j.ijmmb.2025.100793\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Cefiderocol is a parenteral catechol-type siderophore cephalosporin, which has been approved for the treatment of Gram-negative bacterial infections. Its activity among the carbapenem-resistant Gram-negative bacilli (CR-GNBs) in India is largely unknown.</div></div><div><h3>Methodology</h3><div>We tested <em>in-vitro</em> susceptibility of cefiderocol in 84 CR-GNB [ carbapenem-resistant <em>Acinetobacter baumannii</em> (CRAB), carbapenem-resistant <em>Pseudomonas aeruginosa</em> (CRPA), carbapenem-resistant <em>Escherichia coli</em> (CREC) and carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP)] by broth microdilution (BMD) and disc diffusion (DD) using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and concordance of DD was compared with BMD. Cefiderocol susceptibility was evaluated based on the presence of <em>bla</em><sub>NDM</sub> and <em>bla</em><sub>OXA-48</sub> genes.</div></div><div><h3>Results</h3><div>Following CLSI and EUCAST breakpoints, 76.2% [CRKP: 95.65% (22/23); CRPA: 80% (16/20); CREC: 65% (13/20); CRAB: 61.9% (13/21)] and 52.3% [ CRKP: 82.6% (19/23); CRPA: 50% (10/20); CREC: 20% (4/20)] of CR-GNBs were observed susceptible to cefiderocol, respectively. The susceptibility to cefiderocol was seen higher with lower MIC<sub>50</sub> and MIC<sub>90</sub> values for CRKP [1 μg/ml; 4 μg/ml ] and CRPA [2 μg/ml; 8 μg/ml ] in comparison to the other two groups of organisms. The categorical agreement between BMD and DD was found between 90% and 100% for all organisms. Cefiderocol susceptibility among the isolates harbouring <em>bla</em><sub>NDM</sub>, <em>bla</em><sub>OXA-48</sub>, and both <em>bla</em><sub>NDM</sub> and <em>bla</em><sub>OXA-48</sub> genes was observed 75% (24/32); 100% (3/3); and 66.6% (4/6), respectively.</div></div><div><h3>Conclusion</h3><div>Cefiderocol demonstrated high <em>in-vitro</em> activity against CRKP and CRPA isolates from India with lower MIC<sub>50</sub> and MIC<sub>90</sub> irrespective of the presence of <em>bla</em><sub>NDM</sub> and <em>bla</em><sub>OXA-48</sub> genes.</div></div>\",\"PeriodicalId\":13284,\"journal\":{\"name\":\"Indian Journal of Medical Microbiology\",\"volume\":\"54 \",\"pages\":\"Article 100793\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0255085725000064\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085725000064","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Cefiderocol是一种肠外儿茶酚型铁载体头孢菌素，已被批准用于治疗革兰氏阴性细菌感染。它在印度耐碳青霉烯革兰氏阴性杆菌（CR-GNBs）中的活性在很大程度上是未知的。方法:我们对84种CR-GNB[耐碳青霉烯鲍曼不动杆菌（CRAB），耐碳青霉烯铜绿假单胞菌（CRPA），采用临床与实验室标准协会（CLSI）和欧洲抗菌药物敏感性试验委员会（EUCAST）对耐碳青霉烯型大肠埃希菌（CREC）和耐碳青霉烯型肺炎克雷伯菌（CRKP）进行肉汤微量稀释（BMD）和盘片扩散（DD）检测，比较DD与BMD的突破点和一致性。根据blaNDM和blaOXA-48基因的存在来评估头孢地罗的敏感性。结果：遵循CLSI和EUCAST断点，76.2% [CRKP: 95.65% (22/23);CRPA: 80%(16/20);CREC: 65%(13/20);CRAB: 61.9%(13/21)]和52.3% [CRKP: 82.6% (19/23)]；CRPA: 50% (10/20);CREC: 20%(4/20)]的cr - gnb分别对头孢地罗敏感。与其他两组生物相比，CRKP [1 μg/ml；4 μg/ml]和CRPA [2 μg/ml；8 μg/ml]的MIC50和MIC90值较低，对头孢地罗的敏感性较高。所有生物的BMD和DD之间的分类一致性在90%-100%之间。携带blaNDM、blaOXA-48、blaNDM和blaOXA-48基因的分离株对头孢地罗的敏感性为75% (24/32)；100% (3/3)；66.6%（4/6）。结论：Cefiderocol对来自印度的CRKP和CRPA分离株具有较高的体外活性，无论是否存在blaNDM和blaOXA-48基因，其MIC50和MIC90都较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In-vitro susceptibility of cefiderocol and other comparators in carbapenem-resistant Gram-negative bacilli: A study from India

Introduction

Cefiderocol is a parenteral catechol-type siderophore cephalosporin, which has been approved for the treatment of Gram-negative bacterial infections. Its activity among the carbapenem-resistant Gram-negative bacilli (CR-GNBs) in India is largely unknown.

Methodology

We tested in-vitro susceptibility of cefiderocol in 84 CR-GNB [ carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Escherichia coli (CREC) and carbapenem-resistant Klebsiella pneumoniae (CRKP)] by broth microdilution (BMD) and disc diffusion (DD) using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and concordance of DD was compared with BMD. Cefiderocol susceptibility was evaluated based on the presence of bla_NDM and bla_OXA-48 genes.

Results

Following CLSI and EUCAST breakpoints, 76.2% [CRKP: 95.65% (22/23); CRPA: 80% (16/20); CREC: 65% (13/20); CRAB: 61.9% (13/21)] and 52.3% [ CRKP: 82.6% (19/23); CRPA: 50% (10/20); CREC: 20% (4/20)] of CR-GNBs were observed susceptible to cefiderocol, respectively. The susceptibility to cefiderocol was seen higher with lower MIC₅₀ and MIC₉₀ values for CRKP [1 μg/ml; 4 μg/ml ] and CRPA [2 μg/ml; 8 μg/ml ] in comparison to the other two groups of organisms. The categorical agreement between BMD and DD was found between 90% and 100% for all organisms. Cefiderocol susceptibility among the isolates harbouring bla_NDM, bla_OXA-48, and both bla_NDM and bla_OXA-48 genes was observed 75% (24/32); 100% (3/3); and 66.6% (4/6), respectively.

Conclusion

Cefiderocol demonstrated high in-vitro activity against CRKP and CRPA isolates from India with lower MIC₅₀ and MIC₉₀ irrespective of the presence of bla_NDM and bla_OXA-48 genes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.